DWQA Questions › Tag: fluvoxamine
Filter:AllOpenResolvedClosedUnanswered
Will further clinical studies of fluvoxamine in patients with COVID-19 be suppressed by the US medical establishment as they have done for hydroxychloroquine?
ClosedNicola asked 4 years ago • 
367 views0 answers0 votes
In a preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration. There was clinical deterioration in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. Is this a worthwhile agent for COVID-19 management? How would it compare with hydroxychloroquine or ivermectin?
ClosedNicola asked 4 years ago • 
357 views0 answers0 votes
An osteopathic physician and frequent spokesperson on the Internet says there are at least 10 ways that the SARS-CoV-2 mRNA vaccines can cause serious side effects in human recipients. Is this the case, or an exaggeration? Why is she beating this drum?
ClosedNicola asked 4 years ago • 
568 views0 answers0 votes
Ask Question